We’re committed to our mission of finding new treatments that may help improve the lives of people with cancer. Our clinical trials for breast cancer study investigational medications alone, or in combination with other study medications, or standard of care therapy. We perform these trials to see if they can help prevent, find, or treat cancer.
For patients with hormone receptor positive breast cancer
There are three different receptors that are commonly found in breast cancer cells: the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor, receptor 2 (HER-2). When the hormones estrogen and progesterone attach to their receptors, they are activated and fuel cancer growth. Active HER-2 also fuels cancer growth. When any of these receptors are present on the cell, non-chemotherapy treatments that block these receptors, such as hormone therapy or HER-2 targeted therapy, work either alone or in combination with chemotherapy to kill cancer cells or stop their growth.
For patients with triple negative breast cancer (TNBC)
Triple negative breast cancer represents 10 to 15% of all breast cancers. A TNBC diagnosis means that the cancer cells have tested negative for the 3 different receptors that are commonly found on breast cancer cells: the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER-2). When these receptors are not present on the cell, non-chemotherapy treatments that block these receptors, such as hormone therapy or targeted therapy, do not work and the only treatment available is chemotherapy.